Pediatric and Rare Cancers: Translational Challenges and Innovations
Session Overview
Pediatric and rare cancers present a distinct set of scientific and clinical challenges, where tumor biology intersects with developmental processes, patient populations are small, and therapeutic development lags behind common adult malignancies. These cancers demand specialized research paradigms that address unique molecular drivers, the vulnerability of developing organs to toxicity, and the logistical hurdles of conducting trials in small, dispersed populations. This session brings together pediatric oncologists, translational scientists, clinical trialists, and survivorship experts to explore innovative strategies to accelerate progress for these often-neglected diseases.
Why This Session Matters Now
Despite dramatic improvements in survival for some pediatric cancers, others remain stubbornly resistant to treatment, and the long-term health consequences for survivors are significant. For rare cancers in all age groups, the traditional drug development pathway is frequently non-viable. Advances in genomic sequencing and molecular classification are revealing new, targetable vulnerabilities, while novel collaborative trial models and regulatory pathways are emerging to overcome the challenges of small sample sizes. This session addresses the urgent need to build a more agile, biology-driven, and globally connected research ecosystem dedicated to these underserved patient groups.
Key Scientific and Clinical Themes
Molecular Biology of Pediatric and Rare Tumors
Examination of the distinct genetic, epigenetic, and developmental pathways that drive oncogenesis in childhood and rare cancers, moving beyond histological classification to a molecular taxonomy that informs therapy.
Precision Oncology Approaches in Pediatric Cancers
Analysis of the experience with and evidence for molecularly-guided therapy in pediatrics, including the use of targeted agents, the challenges of off-label drug use, and the development of pediatric-specific biomarker-stratified basket trials.
Clinical Trial Design for Rare and Pediatric Malignancies
Discussion of innovative statistical and operational methodologies, such as Bayesian adaptive designs, master protocols, multi-arm trials, and seamless phase I/II designs, to maximize learning from limited patient numbers.
Long-Term Survivorship and Late Effects in Children
Focus on the lifelong health surveillance of pediatric cancer survivors, understanding the mechanisms of late cardiopulmonary, endocrine, cognitive, and second malignant neoplasms, and developing interventions for risk reduction and management.
Novel Therapeutic Targets and Drug Development
Exploration of emerging therapeutic modalities with particular relevance for pediatric and rare cancers, including next-generation cellular therapies, protein degradation strategies, and drugs targeting fusion oncoproteins and developmental pathways.
Global Challenges in Pediatric and Rare Cancer Care
Critical appraisal of disparities in diagnosis, treatment access, and outcomes worldwide, and the role of international consortia, twinning programs, and technology transfer in building capacity and advancing equitable care.
Nature of Research in This Field
Research in pediatric and rare cancers is defined by necessity for deep collaboration and resource sharing. It is characterized by large-scale international molecular profiling initiatives (e.g., Pediatric Cancer Genome Project), consortia-driven clinical trials, and long-term cohort survivorship studies. The literature heavily emphasizes comprehensive review and synthesis to guide practice where Level I evidence is scarce. The field is at the forefront of developing regulatory-accepted novel endpoints and trial designs acceptable for drug approval in small populations.
Who Should Attend
This session is designed for:
- Pediatric oncologists and rare disease specialists
- Translational scientists studying developmental biology and rare tumor genetics
- Clinical trial statisticians and methodology experts
- Survivorship researchers and late-effects clinicians
- Pharmaceutical and biotech researchers focused on niche indications and pediatric development
- Global health advocates and policymakers
Session Perspective
Curing a child or a patient with a rare cancer requires a different playbook—one that prioritizes biology over market size, collaboration over competition, and a lifetime view of health over short-term endpoints. This session provides a platform to champion the specific strategies needed to overcome the “translational valley of death” for these diseases. By connecting cutting-edge molecular discovery with pragmatic innovations in trial design and a steadfast commitment to survivorship, the discussion aims to catalyze a more inclusive and effective model of oncology that leaves no patient group behind.
If your research aligns with this session, we invite you to submit an abstract for consideration.
